Ann-Marie Campbell

This inventor holds 59 USPTO granted patents and 13 published patent applications, plus 6 CIPO patents and 12 EPO patents, primarily in Mutant Isocitrate Dehydrogenase (CPC class C07D). Top assignees: Forma Therapeutics, Inc., Bayer Pharmaceuticals Corporation, Valo Early Discovery, Inc.. Active years: 2000-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ann-Marie Campbell. Retrieved from https://idiyas.com/inventor/ann-marie-campbell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 59 (Patent Applications = 13)

% Patents Active = 62.7

CIPO Patents = 6 (Patent Applications = 1)

EPO Patents = 12 (Patent Applications = 16)

Average Co-Inventor Count = 8.5

ph-index = 17

Forward Citations = 691(Granted Patents)

Forward Citations (Not Self Cited) = 328(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

31 out of 125

Forma Therapeutics, Inc.

patents

6 out of 71

Bayer Pharmaceuticals Corporation

patents

5 out of 15

Valo Early Discovery, Inc.

Cara Therapeutics, Inc.

Bayer Intellectual Property Gmbh

Smithkline Beecham Corporation

patents

11. 1 out of 834,513

Other

patents

Years Active: 2000-2025

Loading Chart...

Areas of Expertise:

Mutant Isocitrate Dehydrogenase

Ubiquitin-Specific Protease 7

Pyridin-2(1H)-one

Quinolinone Derivatives

Pyrrolo

Pyrazolopyrimidines

Quinazolinones

Azaquinazolinones

Fused-Bicyclic Aryl

Pyrrolotriazinones

Thienopyrimidinones

Phenyl Quinolinone

59 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12275715 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2025-04-14),

2. 12018030 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors (2024-06-25),

3. 11795171 - Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors (2023-10-24),

4. 11739071 - Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors (2023-08-29),

5. 11498913 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2022-11-15),

6. 10981915 - Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors (2021-04-20),

7. 10934299 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors (2021-03-02),

8. 10927130 - Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors (2021-02-23),

9. 10906916 - Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors (2021-02-02),

10. 10889567 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2021-01-12),

11. 10836741 - Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors (2020-11-17),

12. 10807976 - Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors (2020-10-20),

13. 10577329 - Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2020-03-03),

14. 10550099 - Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors (2020-02-04),

15. 10550098 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2020-02-04),

Title: Inventor Ann-Marie Campbell: Pioneering Innovations in Monroe, CT

Introduction: Ann-Marie Campbell is a visionary inventor based in Monroe, CT, known for her groundbreaking contributions to various industries.

Latest Patents: Ann-Marie Campbell holds several patents in the fields of technology, healthcare, and sustainability, showcasing her diverse range of expertise.

Career Highlights: With a career spanning over two decades, Ann-Marie Campbell has worked with renowned research institutions and companies to develop cutting-edge solutions that have revolutionized the way we live and work.

Collaborations: Throughout her career, Ann-Marie Campbell has collaborated with top inventors, patent attorneys, and leading companies to bring her ideas to life, fostering a culture of innovation and excellence.

Conclusion: Ann-Marie Campbell's passion for innovation and her relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.